Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
As the Director of Commercial Data Science reporting to the SVP of Commercial Strategy and Operations, you will who will play a pivotal role in Olema’s commercialization efforts by enabling strategic decision-making, utilizing advanced data analytics and machine learning techniques to optimize commercial performance. This individual will work cross-functionally to develop the roadmap and strategic application of data science (inclusive of predictive analytics, AI and machine learning). Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Bachelor's degree in Marketing, Business, Life Sciences, or related field required. Advanced degree preferred
- 10+ years of relevant work experience, including 8+ years in data science or advanced analytics, with a focus on commercial applications in the biotechnology or pharmaceutical industry
- Strong understanding of biotech or pharmaceutical market dynamics, patient access, healthcare system intricacies, and regulatory requirements
- Ability to develop and implement strategic marketing initiatives, with a data-driven approach and strong analytical skills
- Excellent verbal and written communication skills, with the ability to convey complex information clearly and empathetically to patients and healthcare providers
- Proven ability to work effectively across functions and lead collaborative initiatives with internal and external stakeholders
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs · San Francisco Bay Area